Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Operations: 2022-2025

Historic Cash from Operations for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$30.4 million.

  • Stoke Therapeutics' Cash from Operations fell 40.49% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.8 million, marking a year-over-year increase of 162.68%. This contributed to the annual value of -$86.9 million for FY2024, which is 7.13% down from last year.
  • As of Q3 2025, Stoke Therapeutics' Cash from Operations stood at -$30.4 million, which was down 19.45% from -$25.4 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Cash from Operations ranged from a high of $131.8 million in Q1 2025 and a low of -$30.4 million during Q3 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$21.6 million (2024), whereas its average is -$8.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 165.73% in 2023, then soared by 636.62% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Cash from Operations (Quarterly) stood at -$22.4 million in 2022, then grew by 7.71% to -$20.6 million in 2023, then decreased by 12.32% to -$23.2 million in 2024, then plummeted by 40.49% to -$30.4 million in 2025.
  • Its last three reported values are -$30.4 million in Q3 2025, -$25.4 million for Q2 2025, and $131.8 million during Q1 2025.